PLSE - NASDAQ
Pulse Biosciences, Inc.
$24.99
+1.3%Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
At a Glance
Live SnapshotPulse Biosciences, Inc. Management Team
Mr. Kevin P. Danahy
Chief Commercial Officer & Principal Executive Officer
Compensation
$616,410
Mr. Jon Skinner
Chief Financial Officer
Dr. Richard Nuccitelli Ph.D.
Chief Science Officer
Mr. Mitchell E. Levinson
Chief Strategy Officer
Compensation
$584,565
Mr. Darrin R. Uecker
Chief Technology Officer & Director
Compensation
$616,410
Mr. Kenneth B. Stratton Esq., J.D.
General Counsel & Corporate Secretary
Mr. Robert W. Duggan
Independent Co-Chairman
Compensation
$9,126
Mr. Paul Arthur LaViolette
President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board
Compensation
$52,916
Ms. Patty Perla
Vice President of Human Resources
Mr. Edison Manuel
Vice President of Operations
Pulse Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.30M and sold $2.94M worth of PLSE shares, resulting in $10.36M of net buying activity.
3 Months
675.2K
13.30M
0
0.00
+13.3M
+$13.30M
3-6 Months
0
0.00
125.0K
2.93M
-2.9M
-$2.93M
6-9 Months
0
0.00
4.6K
7.04K
-7K
-$7K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Duggan Robert W
Director, 10 Percent Owner:
$13.00M
Laviolette Paul A
Director, Officer: Chief Executive Officer
$295K
Top Sellers
Danahy Kevin Patrick
Officer: Chief Commercial Officer
$2.94M
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $10.36M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
PLSE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 11, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | October 28, 2025 | December 09, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | September 03, 2025 | September 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 27, 2023 | December 19, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | April 14, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 01, 2022 | May 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | April 14, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 14, 2020 | April 14, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 01, 2019 | April 01, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.